WP
CGEM icon

Woodline Partners’s Cullinan Oncology CGEM Stock Holding History

Woodline Partners’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-81,741
Closed -$619K – 937
2025
Q1 		$619K Sell
81,741
-85,574
-51% -$821K ﹤0.01% 812
2024
Q4 		$2.04M Buy
+167,315
New +$2.41M 0.01% 646
2023
Q1 		– Sell
-195,839
Closed -$2.07M – 651
2022
Q4 		$2.07M Buy
+195,839
New +$2.38M 0.03% 467
2022
Q3 		– Sell
-818,572
Closed -$10.5M – 761
2022
Q2 		$10.5M Buy
818,572
+343,514
+72% +$3.9M 0.16% 170
2022
Q1 		$4.97M Hold
475,058
– – 0.08% 245
2021
Q4 		$7.33M Hold
475,058
– – 0.11% 241
2021
Q3 		$10.7M Sell
475,058
-86,148
-15% -$2.3M 0.18% 152
2021
Q2 		$14.5M Buy
561,206
+18,294
+3% +$563K 0.27% 100
2021
Q1 		$22.6M Buy
+542,912
New +$22M 0.5% 62

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Woodline Partners's CGEM Position: Q2 2025 in Review

Woodline Partners sold out of Cullinan Oncology (CGEM) in Q2 2025, closing a stake of 81,741 shares — an estimated $619K sold.

Woodline Partners first reported a position in CGEM in Q1 2021 and held it in 9 quarters. The position peaked at $22.6M in Q1 2021. 143 funds tracked by Wall St. Rank hold CGEM as of Q2 2025.

  • Woodline Partners reported no remaining Cullinan Oncology position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 81,741 Cullinan Oncology shares in Q2 2025, an estimated $619K.
  • Woodline Partners first reported a position in Cullinan Oncology in Q1 2021 and held it in 9 quarters.
  • Woodline Partners's Cullinan Oncology position peaked at $22.6M in Q1 2021.
  • 143 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.